Category: Biosimilars
Biosimilars market research reports by FirstWord
-
Biosimilars: US Payer Perspectives
Biosimilars: US Payer Perspectives Establishing biosimilar interchangeability, patent litigation, negative stakeholder attitudes, poor discounts, and defensive originator strategies have underpinned the sluggish development of the US biosimilar market. So, what would payers like to see? Will adalimu ... Read More
-
US Public Health Spending on Biosimilars: a data driven analysis
US Public Health Spending on Biosimilars: a data driven analysis Which companies and products are shaping the US biosimilar public health spending sector? Biosimilars are a useful way to contain pharmaceutical expenditure for both payers and patients. By the end of 2020, the FDA had approved 29 bios ... Read More
-
Biosimilars: US Payer Insights
Biosimilars: US Payer Insights Why might 2023 be a good year for the US biosimilars market? Delayed regulation, stakeholder anxieties, disappointing discounts and aggressive originator defence strategies have all played their part in the sluggish US biosimilar sector development. But is that about t ... Read More
Research Assistance
